## SHANGHAI XING LING SCI AND TECH PHARMACEUTICAL COMPANY LTD: FEELING DIZZY? DO YOU HAVE A CORONARY HEART DISEASE?

The word, quack-salver, must have – or should have been – a Chinese word because quackery, derived from Dutch word, quack-salver, is alive and well in the People's Republic of China (PRC).

In fact, quackery, quacks, and quack-salvers are proliferating in the PRC at what appears to be an unprecedented level.

There are many public companies, listed on The Stock Exchange of Hongkong Ltd, that make claims that would appear to be nothing short of the ramblings of quacks.

Shanghai Xing Ling Sci and Tech Pharmaceutical Company Ltd (Code 8105, The Growth Enterprise Market [The GEM] of The Stock Exchange of Hongkong Ltd) has all the outward appearances of being quackery, dressed up to look as though it is a respectable pharmaceutical company.

This Company, which went public on July 31, 2002, makes the claim, at Page 76 of its Prospectus, of being in the business of research and development, manufacture and sale, of Chinese medicines.

This is the way that it describes its activities:

'The Company is principally engaged in the research and development, manufacture and sale of Chinese medicine products. At present, the Company manufactures five types of Chinese medicine products. Two of them are modern Chinese medicine preparations, namely Ginkgo Granule and Ginkgo Leaf Tablet. The remaining three products are bulk pharmaceuticals, which include bulk pharmaceuticals for Ginkgo Granule and Ginkgo Leaf Tablet, namely BGE50 and bulk pharmaceuticals for artificial musk, namely Haikesu I and Haikesu II ... The composition, preparation method and uses of ginkgo biloba invented by the Company's researchers were granted the patent registration by the United States Patent and Trademark Office in 2000 and 2001. Set out below are the Company's products:

Chinese Medicine Preparation	Physical Form	Therapeutic Effects/Usage	Chinese New Medicine Category	OTC/ Prescription Medicine	Admitted to the State Medical Insurance Scheme	Date of Launch
Ginkgo Leaf Tablet	Green Tablet	For the treatment of stroke and pectoral pain	N/A	Prescription Medicine	Yes	April 1994
Ginkgo Granule	Brown Granule	For the treatment of coronary heart disease, angina pectoris and vertigo	Category II	Prescription Medicine	No	May 2000
Bulk Pharmaceu	ıticals					
GBE50	Brown Powder	Bulk pharmaceutical for Ginkgo	Category II	N/A	N/A	May 2000

		Granule/Ginkgo Leaf Tablet				
Haikesu I	White Powder	Bulk pharmaceutical for artificial musk	Category I	N/A	N/A	November 1993
Haikesu II	White Powder	Bulk pharmaceutical for artificial musk	Category I	N/A	N/A	November 1993

## **Definitions**:

- 1. 'Artificial Musk' is defined at Page 33 as 'a Chinese medicine which is in the form of brown-yellow powder and is a kind of catalyst.'
- 2. 'Ginkgo' is defined as 'a fruit of a deciduous tree native to China and having fan shaped leaves and fleshy yellowish seeds with a disagreeable odour.

  The male plants are often grown as ornamental street trees.' (This definition is copied, straight out of the Random House Webster's College Dictionary Editor)
- 3. *'Ginkgo Biloba'* is defined as being the botanic name of ginkgo in Latin

According to Page 77 of the Prospectus, the efficacy rate of Ginkgo Granules reached an average of about 93.50 percent, 92.20 percent and 92 percent for coronary heart disease, angina pectoris and vertigo, respectively, compared with the average rate of another similar product.

Angina pectoris is, merely, a condition, such as a sore throat, that causes intense pain, while vertigo is, simply put, dizziness, sometimes associated with a person's fear of high places.

Coronary heart disease is ... CLICK TO ORDER FULL ARTICLE

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

If readers feel that they would like to voice their opinions about that which they have read in TARGET, please feel free to e-mail your views to <a href="editor@targetnewspapers.com">editor@targetnewspapers.com</a> or <a href="targnews@hkstar.com">targnews@hkstar.com</a>. TARGET does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.

